(Tiper Stock Exchange) – Registera multinational pharmaceutical company that is part of the FTSE MIB, closed the first quarter of 2023 with consolidated net revenues equal to 551.4 million euros, up by 31.5% compared to the first quarter of the previous year or +21% on a like-for-like basis and at constant exchange rates, driven by the excellent performance of all business areas and by the success of the integration of EUSA Pharma contributing €47.7 million in the quarter, with a slightly negative exchange rate effect of €2.7 million (-0.6%).
L’EBITDA is equal to 220.8 million euros, up by 35.4% compared to the first quarter of 2022, with an incidence on revenues of 40%. L’Net income is equal to 124 million euro, up by 28.2%. L’adjusted net profit is equal to 155 million euro, up by 33.3%.
“The first quarter financial results confirm theRecordati’s ability to consistently achieve exceptional results and show, even net of extraordinary or temporary factors, an excellent start to the year for both business units – commented l‘AD Rob Koremans – The Specialty and Primary Care segment outperformed its peer markets on continued improved competitiveness, with solid double-digit growth across all of our key therapy areas.”
“Products for the treatment of rare diseases also maintained strong momentum, with excellent results from endocrinology products and for the successful integration of the oncology portfolio. We are grateful for the continued efforts of all colleagues,” he added. “Today, we confirm our commitment to performancerevising our full-year 2023 targets upwards, with revenues and earnings now above the high end of our guidance in February.”
Goals revised upwards for 2023: revenues at 2,050 – 2,090 million euros (vs. previous 1,970 – 2,030 million), EBITDA at 750 – 770 million euros (vs. previous 700 – 730 million) and adjusted net profit at 490 – 500 million euros (vs. previous 470 – €490 million).